Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Estimation of Maximum Tolerable Dose (MTD) and Minimum Efficient Dose (MED) of BP-C1 in Stage IV Breast Cancer Patients: A Phase I Dose-response Study

NCT04298333 is registered in ClinicalTrials.gov with Meabco A/S as lead sponsor.

NCT NCT04298333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04298333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Estimation of Maximum Tolerable Dose (MTD) and Minimum Efficient Dose (MED) of BP-C1 in Stage IV Breast Cancer Patients: A Phase I Dose-response Study
Lead sponsor
Meabco A/S
Phase
Phase 1
Overall status
Completed
Start date
June 27, 2009
Completion date
January 4, 2011
Enrollment
18 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer, stage iv breast cancer